## 

APOTEX INC., Petitioner

v.

CELGENE CORPORATION,
Patent Owner

Case IPR2023-00512 Patent 8,846,628

JOINT REQUEST THAT SETTLEMENT AGREEMENTS BE TREATED AS BUSINESS CONFIDENTIAL INFORMATION AND BE KEPT SEPARATE PURSUANT TO 35 U.S.C. § 317(b) AND 37 C.F.R. § 42.74



Pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c), Petitioner Apotex Inc. ("Apotex" or "Petitioner") and Patent Owner Celgene Corporation ("Celgene" or "Patent Owner") jointly request that the Settlement Agreement between the parties (Ex. 1060) filed concurrently herewith, as referenced in the Joint Motion to Terminate Proceeding, (a) be treated as business confidential information, (b) be kept separate from the file of the involved patent, and (c) be made available only as permitted pursuant to the provisions of 37 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c). The Board previously provided authorization to file this Joint Request on January 3, 2024. (Jan. 3, 2024, email from E. Goldschlager on behalf of the Board).

January 4, 2024 Respectfully submitted,

/s/ Vishal C. Gupta

Vishal C. Gupta (Reg. No. 67,284)

Steptoe LLP

1114 Avenue of the Americas

New York, NY 10036

Tel: (212) 506-3900

Counsel for Petitioner Apotex Inc.

January 4, 2024

Respectfully submitted, /s/Heather M. Petruzzi/

Heather M. Petruzzi (Reg. No. 71,270)

Wilmer Cutler Pickering Hale and Dorr

LLP

2100 Pennsylvania Avenue NW

Washington, DC 20037

Tel: (202) 663-6000

Counsel for Celgene Corporation



## **CERTIFICATE OF SERVICE**

I hereby certify that on January 4, 2024, I caused a true and correct copy of the foregoing Joint Request that Settlement Agreements be Treated as Business Confidential Information and be Kept Separate Pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74 to be served via e-mail on all counsel of record.

By: /s/ Vishal Gupta Vishal Gupta (Reg. No. 67,284) Steptoe LLP 1114 Avenue of the Americas New York, NY 10036 Tel: (212) 506-3900

